Can a stem cell treatment help someone with ALS live longer or regain an ability the disease had taken away? The new Tennessee stem cell law has pushed that question into the spotlight through a powerful FOX 17 News report about Ashley Vickers, a Tennessee mother who has lived with ALS for a decade.1
Her story deserves respect, attention, and honest curiosity. It also deserves something every patient facing a serious disease needs: a clear line between a meaningful personal outcome and proof that a treatment works.
Watch the FOX 17 News Report
The June 29, 2026 report by Dennis Ferrier follows Ashley, her husband Randy, and the team at Vita Nova Stem Cell Institute in Franklin, Tennessee.1
The segment says Ashley was diagnosed with amyotrophic lateral sclerosis, or ALS, 10 years earlier. It also reports that she has received stem cell treatments and recently stood with assistance after losing that ability years ago.1
That moment is emotionally powerful. A family living under the weight of an incurable disease has every right to celebrate a gain that once felt out of reach.
Still, we cannot leap from “this happened after treatment” to “the treatment caused this result.” That jump is the medical version of seeing rain after washing the car and deciding the car wash controls the weather.
What the News Report Claims
FOX 17 presents Ashley’s experience as an exceptional case. The report quotes Dr. Hemal Mehta as saying the therapy is not a cure but may slow ALS progression, and it describes patients surviving as long as 10 years while receiving stem cell therapy.1
The report also says Ashley regained the ability to stand. It does not provide clinical records, standardized ALS function scores, treatment dates, cell type, dose, delivery method, comparison data, or a published study tied to her outcome.1
| What the report shows | What the report does not establish |
|---|---|
| Ashley has lived with ALS for 10 years | That stem cells caused her longer survival |
| She receives stem cell treatments | Which exact product, dose, or protocol was used |
| She stood with physical assistance | Whether a clinician measured a sustained functional improvement |
| Her physician says treatment may slow decline | Results from a randomized, controlled clinical trial |
| The family reports hope and more time together | Safety and effectiveness for other people with ALS |
A patient story can be the spark that starts research. It cannot replace the research.
What the Tennessee Stem Cell Law Changes
Tennessee Public Chapter 1016, passed as House Bill 2246, was signed on May 19, 2026 and took general effect on July 1, 2026.2 The law allows physicians to perform certain stem cell or regenerative medicine therapies that are not approved by the U.S. Food and Drug Administration when the treatment falls within the physician’s scope of practice.2
The law sets state-level requirements for product sourcing, documentation, consent, advertising, and adverse-event reporting. It also encourages physicians to participate in clinical outcomes registries.2
Key patient protections in the law
| Requirement | What it means for patients |
|---|---|
| Clear advertising notice | Ads must state that the therapy has not been approved by the FDA |
| Written consent | The patient or legal representative must sign before treatment |
| Product documentation | Physicians must obtain products from facilities that meet listed standards |
| Adverse-event reporting | Physicians must report events to licensing authorities and, in some cases, manufacturers or accrediting bodies |
| Scope-of-practice rule | The physician must provide treatment within the boundaries of their licensed practice |
These guardrails matter. Patients deserve to know when they are being offered an unapproved intervention, and providers should not hide that fact behind glossy language.
However, the law does not declare a stem cell product safe or effective for ALS. It does not turn an unapproved therapy into an FDA-approved treatment, and it does not replace a controlled clinical trial.2
For a broader look at how state and federal oversight fit together, read our guide to government regulations for stem cell clinics.
Legal Access Is Not the Same as FDA Approval
This distinction is the backbone of the story. A state can define how licensed clinicians offer a service under state law, but federal approval asks a different question: has a specific product been tested well enough for a specific medical use?
The FDA says regenerative medicine therapies have not been approved to treat ALS or other neurological disorders.3 Harvard Stem Cell Institute also states that there are no FDA-approved stem cell treatments for ALS, although researchers continue to test cell-based approaches in clinical trials.4
| Term | What it actually tells us |
|---|---|
| Facility registration | A facility has completed a regulatory registration step |
| Product testing documents | A product lot has specified laboratory records |
| ClinicalTrials.gov listing | A study has been registered in a public database |
| State-law permission | A physician may provide a therapy under state requirements |
| FDA approval | A specific product has met federal standards for a defined use |
These labels are not interchangeable. The FDA warns that facility registration or a ClinicalTrials.gov listing does not mean a product is legally marketed or proven effective.3
Patients should ask whether the cells come from their own body or a donor because the handling, immune risks, and regulatory questions can differ. Our explanation of autologous versus allogeneic stem cells can help make that conversation clearer.
What Science Says About Stem Cells for ALS
ALS damages motor neurons, the nerve cells that control voluntary movement. As those cells fail, people can lose the ability to walk, use their hands, speak, swallow, and breathe.5
Stem cell research in ALS follows several strategies. Some approaches aim to support surviving neurons, reduce harmful inflammation, deliver protective factors, or eventually replace damaged cells.5
A 2024 scientific review examined mesenchymal stem cells, neural stem cells, and induced pluripotent stem cells for ALS.6 The authors found promising signals, but they also highlighted small study sizes, nonrandomized designs, cell-integration challenges, and safety questions that require larger controlled trials.6
That is a long way from saying the field has failed. It means the field is still building the bridge, and patients should not be told the bridge is finished while researchers are still testing its supports.
Why one exceptional outcome cannot prove effectiveness
ALS does not progress at the same rate in every person. Survival can vary, and changes in strength or function can be shaped by disease subtype, supportive care, respiratory care, nutrition, medications, rehabilitation, measurement methods, and other factors.5
To show that a therapy slows disease, researchers usually need standardized measurements, adequate follow-up, a comparison group, transparent safety reporting, and enough participants to separate a treatment effect from natural variation. The FOX 17 report does not present that kind of dataset.1
Ashley’s experience can still be important. It may support a reason to investigate, document, and test the protocol, but it should not be used as a promise to another family.
The Safety Questions the Report Leaves Open
The report does not identify the exact cell product or explain its risks. That missing information is not a footnote because “stem cell therapy” is an umbrella term, much like “vehicle” can mean a bicycle, an ambulance, or a tractor.
The FDA has received reports involving unapproved regenerative products that include infections, unwanted immune reactions, neurological events, blindness, and tumor formation.3 Those reports do not prove that every product carries the same risk, but they show why product identity, manufacturing controls, delivery route, and follow-up matter.
Before paying for treatment, families should know how to vet a stem cell therapy provider and recognize the difference between transparent evidence and a sales pitch dressed in a lab coat.
Questions ALS Patients Should Ask Before Treatment
Hope is not the enemy. Unexamined claims are.
Patients and caregivers can protect themselves by bringing direct questions to the treating physician and an independent neurologist who knows the patient’s ALS history.
- What exact cells or tissue product will be used, and where do they come from?
- Is the product FDA-approved for ALS, used under an FDA-authorized clinical trial, or offered only under Tennessee law?
- What is the treatment’s Investigational New Drug number, if one exists?
- What published, peer-reviewed evidence supports this exact protocol?
- How many ALS patients has the clinic treated, and how are outcomes measured?
- Will the clinic share both positive and negative results, including adverse events?
- What are the immediate and long-term risks for this route of administration?
- What is the total cost, including repeat treatment, travel, testing, and follow-up?
- What happens if the disease progresses after treatment?
- Can the patient’s ALS specialist review the protocol before any payment or consent?
Our list of essential questions to ask a stem cell therapy provider offers a printable starting point. Patients can also use our stem cell consultation checklist to organize records and compare answers.
A provider who welcomes scrutiny is showing respect. A provider who pressures a frightened family to decide quickly is waving a red flag with both hands.
What Responsible Hope Looks Like
Responsible hope can hold two truths at once. Ashley Vickers’ story is moving, and the current evidence does not prove that a commercially offered stem cell treatment can stop ALS.
We should celebrate every meaningful day a family gains without turning that family’s experience into a universal claim. People living with ALS have already been handed a brutal diagnosis, so they should not also carry the burden of sorting marketing from medicine alone.
The Tennessee stem cell law creates a new state framework for access and disclosure. Its real test will be whether providers collect transparent outcomes, report harms, publish evidence, and tell patients exactly what is known and unknown.2
For now, the strongest next step is not blind belief or automatic rejection. It is informed consent, independent medical review, careful questions, and a demand for evidence strong enough to match the size of the promise.
References
- FOX 17 News: Stem Cell Therapy Helps ALS Patient Live Beyond All Normal Expectations
- Tennessee Public Chapter No. 1016, House Bill 2246
- FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies
- Harvard Stem Cell Institute: What Stem Cell-Based Therapies Are Available for ALS?
- ALS Association: Stem Cells and ALS
- Stem Cell Therapy for the Treatment of Amyotrophic Lateral Sclerosis: Comparison of MSCs, NSCs, and iPSCs
